Crucell N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 03 apr 2008 - 13:51

Statutaire naam Crucell N.V.

Titel Crucell Announces First in Man Study with New Adenovirus Vector

Bericht Recombinant adenovirus 26 vector avoids pre-existing immunity and is used in new HIV vaccine Leiden, The Netherlands, 3 April 2008 – Dutch biotechnology company Crucell N.V. today announced that the novel recombinant adenovirus serotype 26 (rAd26) vector, which is jointly developed by Crucell and the Beth Israel Deaconess Medical Center (BIDMC), will be used in a phase I clinical study to test a new HIV vaccine. The rAd26 vector is specifically designed to avoid the pre-existing immunity to the more commonly used adenovirus serotype 5 (Ad5), which has recently shown limitations as an HIV vaccine vector. The rAd26 vaccine is the first HIV vaccine candidate that emerges from the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program, which brings together researchers from academia and industry in an effort to accelerate the development of promising HIV/AIDS vaccines. Crucell, Harvard Medical School (HMS) and the BIDMC participate in this program, which is sponsored by the National Institutes of Health (NIH). The phase I clinical study will be conducted at the Brigham and Women’s Hospital (BWH) in Boston and will focus on assessing the safety and immunogenicity of the vaccine. The study will involve 48 healthy volunteers. “The rAd26 vaccine vector has been selected for its particularly low seroprevalence in humans and for its potential immunogenicity and protective efficacy as was shown in preclinical studies”, says Dan H. Barouch, MD, PhD, Associate Professor of Medicine at BIDMC and HMS and Principal Investigator in the IPCAVD program. Jaap Goudsmit, Chief Scientific Officer at Crucell: “The rAd26 vector, as part of our AdVac® technology program, is designed to overcome the problem of pre-existing immunity in humans against the most commonly used recombinant vaccine vector, adenovirus serotype 5.” Antibodies to Ad5, a common cold virus, are widespread among people of all ages and are known to lower the immune response to Ad5-based vacc

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

200804030000000018_Phase I Ad26 HIV_FINAL.pdf (opens in a new window)

Datum laatste update: 24 maart 2025